U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07197307) titled 'Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)' on Sept. 03.
Brief Summary: This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma. Chimeric antigen receptor (CAR)-T cell naive patients who have failed first-line therapy and patients who have received CAR-T cells as second-line therapy and experienced CAR-T failure will be eligible for inclusion.
Study Start Date: Oct. 15
Study Type: INTERVENTIONAL
Condition:
Aggressive Diffus...